These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22208039)

  • 1. [Docetaxel-based combination chemotherapy for castration-resistant prostate cancer].
    Urakami S; Shiina H; Igawa M
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():531-7. PubMed ID: 22208039
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapy-based treatment for castration-resistant prostate cancer.
    Seruga B; Tannock IF
    J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study to castrate-resistant prostate cancer: AUO study AP 60/10].
    Rexer H
    Urologe A; 2011 May; 50(5):607-8. PubMed ID: 21523432
    [No Abstract]   [Full Text] [Related]  

  • 6. [A case on hemodialysis with castration-resistant prostate cancer which responded to combination chemotherapy with docetaxel and prednisolone].
    Ito H; Inamura S; Taga M; Tsuchiyama K; Kusukawa N; Oyama N; Akino H; Yokoyama O
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1245-7. PubMed ID: 24047790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; George DJ
    Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
    Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
    BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
    Hervonen P; Tulijoki T; Kellokumpu-Lehtinen P
    Anticancer Res; 2012 Aug; 32(8):3305-9. PubMed ID: 22843906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.
    Pond GR; Armstrong AJ; Wood BA; Leopold L; Galsky MD; Sonpavde G
    BJU Int; 2012 Dec; 110(11 Pt B):E461-8. PubMed ID: 22520631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of docetaxel based therapy for prostate cancer in the era of targeted medicine.
    Sonpavde G; Sternberg CN
    Int J Urol; 2010 Mar; 17(3):228-40. PubMed ID: 20088874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.
    Loriot Y; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Bossi A; Chauchereau A; Fizazi K
    Eur J Cancer; 2010 Jul; 46(10):1770-2. PubMed ID: 20483588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
    Mathew P; Thall PF; Bucana CD; Oh WK; Morris MJ; Jones DM; Johnson MM; Wen S; Pagliaro LC; Tannir NM; Tu SM; Meluch AA; Smith L; Cohen L; Kim SJ; Troncoso P; Fidler IJ; Logothetis CJ
    Clin Cancer Res; 2007 Oct; 13(19):5816-24. PubMed ID: 17908974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
    Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
    J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
    J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of metastatic castration-resistant prostate cancer after first-line docetaxel.
    Harrington JA; Jones RJ
    Eur J Cancer; 2011 Sep; 47(14):2133-42. PubMed ID: 21658937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer.
    Sella A; Yarom N; Zisman A; Kovel S
    Oncology; 2009; 76(6):442-6. PubMed ID: 19420966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
    Buonerba C; Federico P; D'Aniello C; Rescigno P; Cavaliere C; Puglia L; Ferro M; Altieri V; Perdonà S; De Placido S; Di Lorenzo G
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.
    Beardsley EK; Chi KN
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):161-6. PubMed ID: 18685415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Creel P; Turnbull J; Moore C; Jaffe TA; Haley S; Petros W; Yenser S; Gockerman JP; Sleep D; Hurwitz H; George DJ
    Clin Cancer Res; 2008 Oct; 14(19):6270-6. PubMed ID: 18829508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.